Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Why OmniAb?

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

A unique offering that leverages four species and efficient technology to address critical industry needs

Your therapeutic development relies on discovery of high-quality antibody leads. OmniAb’s proprietary and validated transgenic animals, including OmniRat®, OmniMouse®, and OmniChicken®, are each capable of generating high quality fully human antibodies, naturally optimized through in vivo affinity maturation. OmniTaur, the latest addition to OmniAb animal platforms provides antibodies with cow-inspired ultralong CDR-H3 to bind challenging targets with deep pockets or cryptic epitopes.

Flexible options for transgenic animal species and discovery processes are key to success

Because each human Ig-transgenic host animal provides a distinct immune response profile, the availability of multiple species offers more options to find the ideal therapeutic candidate.

Our project teams work closely with partners to customize and optimize the discovery process for each campaign. You can choose between your internal processes, OmniAb proprietary screening technologies, or methods offered by CROs, such as hybridoma, display libraries, B-cell cloning, and next-generation sequencing.

Access a full range of transgenic animals for your discovery campaigns:

The world’s only human lg-transgenic rats

OmniRat® and OmniFlic® are the only transgenic rats that generate human antibodies for the development of therapeutic monospecific and bispecific antibodies.

Human lg-transgenic mice for maximal flexibility in your discovery processes

OmniMouse® delivers fully human antibodies using standard mouse-based protocols.

The world’s only human lg-transgenic chicken for antibody discovery

OmniChicken® and OmniFlic® are optimized for human antibody research.

OmniTaur™ provides an ultra-long CDR-H3 platform

Discover OmniTaur™.

Common light chain platforms for simplified bispecific antibody generation

Discover OmniFlic® and OmniClic®.

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.